Literature DB >> 2220259

Physical and psychological capabilities during substitution therapy with recombinant growth hormone in adults with growth hormone deficiency.

M Degerblad1, O Almkvist, R Grunditz, K Hall, L Kaijser, E Knutsson, H Ringertz, M Thorén.   

Abstract

In a double-blind cross-over study with recombinant methionyl growth hormone (GH) and placebo during 12 weeks, the effect of GH substitution therapy (0.5-06 IU.kg-1.week-1) on physical performance, muscle strength, bone mineral density, and mood and cognitive functions was investigated in 6 GH-deficient adults. During GH substitution serum concentrations of insulin-like growth factor-I and procollagen-III peptide increased in all 6 patients, whereas concentrations of serum urea decreased. Five of the patients identified the GH period and reported improved well-being with increased mental alertness and vitality and improved physical capacity and muscle strength. There was, however, no change of the isokinetic muscle strength during GH substitution therapy, and the working capacity on the bicycle ergometer was just slightly improved in some patients. The bone mineral density was low and unchanged in all patients. Mood and cognitive functions did not change during GH therapy. A reversible fluid retention was observed in one patient during the GH period. In conclusion, short-term GH substitution therapy to GH-deficient adults induced a subjective improvement of general well-being. Longer treatment periods will be necessary to establish the effect on physical capacity, muscle strength, bone mineral density, and mood and cognitive functions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2220259     DOI: 10.1530/acta.0.1230185

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  13 in total

Review 1.  Ageing, growth hormone and physical performance.

Authors:  F Lanfranco; L Gianotti; R Giordano; M Pellegrino; M Maccario; E Arvat
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 2.  Quality-of-life assessment of adults with growth hormone deficiency. Implications for drug therapy.

Authors:  S P McKenna; L C Doward
Journal:  Pharmacoeconomics       Date:  1994-11       Impact factor: 4.981

Review 3.  Hormones and behaviour.

Authors:  R Fahlbusch; A Barocka
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

4.  Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3.

Authors:  R G Bing-You; M C Denis; C J Rosen
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

5.  The aging brain: is function dependent on growth hormone/insulin-like growth factor-1 signaling?

Authors:  B A Forshee
Journal:  Age (Dordr)       Date:  2006-06-03

6.  [Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: need for additional growth hormone substitution?].

Authors:  C Wüster; E Slenczka; R Ziegler
Journal:  Klin Wochenschr       Date:  1991-10-18

7.  Growth hormone substitution titrated to obtain IGF-I levels in the physiological range in hypopituitary adults: effects upon dynamic strength, endurance and EMG.

Authors:  Bertil Ekman; Björn Gerdle; Hans J Arnqvist
Journal:  Eur J Appl Physiol       Date:  2003-07-26       Impact factor: 3.078

8.  Endocrine functions in long-term survivors of low-grade supratentorial glioma treated with radiation therapy.

Authors:  M J Taphoorn; J J Heimans; E A van der Veen; A B Karim
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 9.  [Growth hormone therapy in adults. Attempt to assess a decade of use].

Authors:  M Faust; C J Strasburger
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

Review 10.  Growth hormone therapy and quality of life in adults and children.

Authors:  Deborah J Radcliffe; Joseph S Pliskin; J B Silvers; Leona Cuttler
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.